Military exposures and lung cancer in United States Veterans

IF 3 3区医学 Q2 ONCOLOGY

Seminars in oncology Pub Date : 2022-06-01 DOI:10.1053/j.seminoncol.2022.06.010

William Grier , Hatoon Abbas , Rediet Regassa Gebeyehu , Ankur Kumar Singh , Jimmy Ruiz , Stella Hines , Fahid Alghanim , Janaki Deepak

{"title":"Military exposures and lung cancer in United States Veterans","authors":"William Grier , Hatoon Abbas , Rediet Regassa Gebeyehu , Ankur Kumar Singh , Jimmy Ruiz , Stella Hines , Fahid Alghanim , Janaki Deepak","doi":"10.1053/j.seminoncol.2022.06.010","DOIUrl":null,"url":null,"abstract":"<div><p>Lung cancer screening begins at age 50, with yearly low dose computed tomography (LDCT) scans until age 80, for patients determined to be high risk due to tobacco smoking. Veterans serving from World War II to the Gulf War are now at the age where LDCT is recommended. This recommendation from the United States Preventative Service Task Force includes patients who have a 20-pack year tobacco history and currently smoke or quit within the last 15 years. This recommendation does not consider additional risk factors such as exposures to lung carcinogens. We discuss unique operational and occupational exposures encountered while serving in the armed forces, which may potentially increase the risk of lung cancers in the Veteran population. The additional risk of lung cancer due to military exposure history is unclear and more work is needed to identify and quantify risk at an individual level. Increasing awareness at the provider level regarding the carcinogenic exposures encountered may allow a larger population of Veterans, not meeting traditional LDCT criteria, to benefit from lung cancer screening.</p></div>","PeriodicalId":21750,"journal":{"name":"Seminars in oncology","volume":"49 3","pages":"Pages 241-246"},"PeriodicalIF":3.0000,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0093775422000501/pdfft?md5=0cfd7b3b1a14eb31f84cbe6a8489bc49&pid=1-s2.0-S0093775422000501-main.pdf","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0093775422000501","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 4

Abstract

Lung cancer screening begins at age 50, with yearly low dose computed tomography (LDCT) scans until age 80, for patients determined to be high risk due to tobacco smoking. Veterans serving from World War II to the Gulf War are now at the age where LDCT is recommended. This recommendation from the United States Preventative Service Task Force includes patients who have a 20-pack year tobacco history and currently smoke or quit within the last 15 years. This recommendation does not consider additional risk factors such as exposures to lung carcinogens. We discuss unique operational and occupational exposures encountered while serving in the armed forces, which may potentially increase the risk of lung cancers in the Veteran population. The additional risk of lung cancer due to military exposure history is unclear and more work is needed to identify and quantify risk at an individual level. Increasing awareness at the provider level regarding the carcinogenic exposures encountered may allow a larger population of Veterans, not meeting traditional LDCT criteria, to benefit from lung cancer screening.

查看原文本刊更多论文

美国退伍军人的军事暴露和肺癌

肺癌筛查从50岁开始，每年进行低剂量计算机断层扫描(LDCT)，直到80岁，对因吸烟而被确定为高风险的患者进行筛查。从第二次世界大战到海湾战争的退伍军人现在已经到了推荐使用LDCT的年龄。美国预防服务工作组的这一建议包括有20包烟草史且在过去15年内吸烟或戒烟的患者。这一建议并未考虑其他风险因素，如接触肺癌物质。我们讨论了在军队服役时遇到的独特的操作和职业暴露，这可能会增加退伍军人患肺癌的风险。由于军事暴露史导致的额外肺癌风险尚不清楚，需要更多的工作来确定和量化个人水平的风险。提高提供者对所遇到的致癌物暴露的认识可能会使更多不符合传统LDCT标准的退伍军人从肺癌筛查中受益。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Seminars in oncology 医学-肿瘤学

CiteScore

6.60

自引率

0.00%

发文量

审稿时长

104 days

期刊介绍： Seminars in Oncology brings you current, authoritative, and practical reviews of developments in the etiology, diagnosis and management of cancer. Each issue examines topics of clinical importance, with an emphasis on providing both the basic knowledge needed to better understand a topic as well as evidence-based opinions from leaders in the field. Seminars in Oncology also seeks to be a venue for sharing a diversity of opinions including those that might be considered "outside the box". We welcome a healthy and respectful exchange of opinions and urge you to approach us with your insights as well as suggestions of topics that you deem worthy of coverage. By helping the reader understand the basic biology and the therapy of cancer as they learn the nuances from experts, all in a journal that encourages the exchange of ideas we aim to help move the treatment of cancer forward.